Charlotte's Web Holdings, Inc. reports developments around its hemp-derived botanical wellness business, including operating results, cost structure updates, product-channel activity, and federal policy affecting CBD and full-spectrum hemp products. The company describes itself as a Certified B Corporation focused on hemp extract wellness, with categories that include CBD tinctures, gummies, capsules, topical creams and lotions, hemp-derived THC microdose gummies, functional mushroom gummies, and CBD pet products.
Recurring updates also cover regulatory and healthcare-access initiatives for eligible hemp products, distribution through retailers, healthcare practitioners, and online channels, and its exposure to cannabinoid pharmaceutical development through DeFloria. News frequently links these themes to product quality controls, vertically integrated operations, shareholder matters, and capital-structure or governance developments.
Charlotte's Web (CWBHF) will report its third-quarter 2026 financial results before market open on November 12, 2026. It will also file its Quarterly Report on Form 10-Q that day.
Instead of a November 12 shareholder call, the company intends to hold one corporate update call and webcast in December, after December 11, when the revised federal definition of hemp is scheduled to take full effect under current law. Charlotte's Web said the timing allows greater federal policy clarity before discussing the implications for the industry and its business, along with other corporate developments. Call details will follow in a separate notice.
Charlotte's Web (CWBHF) welcomed passage of a federal continuing resolution (CR) that extends government funding and delays a planned November 12 ban on naturally derived hemp products. The CR, already passed by both chambers of Congress, now goes to the President for signature.
The measure provides time until December 11, 2026 for Congress to address longer-term policy priorities, including baseline regulations for hemp-derived products. Charlotte's Web highlights the CR’s role in maintaining the prohibition on synthetic cannabinoids while allowing continued access to naturally derived hemp products under existing rules.
The company reiterates its support for science-based federal regulations that distinguish therapeutic, non-intoxicating hemp products from synthetic and high-THC products, emphasizing consumer safety, product integrity, and regulatory certainty for the hemp industry.
Charlotte's Web (OTCQX: CWBHF) announced a strategic partnership with Edibles.com to expand consumer access to its hemp wellness products via Edibles.com's online marketplace and flagship Atlanta store. The curated assortment includes hemp extracts for sleep, focus, and everyday wellness, functional mushroom products, and a topical cream.
According to Charlotte's Web, the collaboration also supports industry efforts to secure federal standards for non-intoxicating hemp as a potential hemp ban approaches on November 12, 2026. Both companies are urging Congress to extend recriminalization measures and finalize a framework for hemp-derived products, following a U.S. Senate Continuing Resolution that would allow sales through December 11, 2026 if fully approved.
Charlotte's Web (OTCQX:CWBHF) launched Route CBD, a multi-city advocacy initiative to support Californians who lost access to full-spectrum hemp CBD following California’s SB 378, AB 8, and related emergency regulations effective July 1, 2026.
From August 11 to September 10, a Route CBD pop-up truck will visit communities along the California–Nevada border, where consumers can share their stories, learn about hemp regulations, engage in advocacy, and legally access Charlotte's Web full-spectrum hemp CBD products. The company links the effort to its long-standing mission around consumer education, product quality, and hemp policy, and it expresses concern about potential nationwide access challenges if a federal hemp ban takes effect on November 12, 2026.
Charlotte's Web (OTCQX: CWBHF) reported second quarter 2026 revenue of $10.9 million, down 15.2% year over year, reflecting its 2025 decision to largely exit retail channels. Gross profit was $5.2 million, with gross margin expanding to 47.5% from 46.8% despite lower volume.
Operating loss was $4.4 million versus $4.1 million a year earlier, while net loss narrowed to $4.1 million from $6.3 million, aided by a favorable change in fair value of financial instruments. Adjusted EBITDA improved to -$3.0 million from -$3.6 million. SG&A declined 5.4% year over year, and second quarter operating cash use fell to $0.9 million from $2.8 million in the first quarter.
On May 28, 2026, British American Tobacco subsidiary BAT converted its C$75.3 million debenture into common shares at C$0.94 and invested an additional $10 million via private placement, eliminating Charlotte's Web's largest liability. Total liabilities dropped by $57.0 million (approximately 74%), shareholders' equity moved to $56.1 million from a $2.0 million deficit, and cash rose to $14.0 million. The Company also completed its transition to in-house gummy production and highlighted evolving U.S. hemp policy, California market restrictions (about 10% of revenue), and progress of the DeFloria clinical program.
Charlotte's Web (OTCQX: CWBHF) welcomed U.S. Senate passage of a Continuing Resolution that would extend federal government funding through December 11, 2026 and delay until November 12, 2026 the enactment of a 0.4 mg THC-per-container limit on finished hemp products.
According to Charlotte's Web, the extension gives Congress more time to develop a bipartisan federal framework for therapeutic, full-spectrum hemp products. The measure now moves to the House, which previously passed a separate CR without hemp provisions. The company noted that a ban on non-naturally produced cannabinoids, including synthetic cannabinoids, is still scheduled to take effect on November 12, 2026 and stated that its products use naturally occurring full-spectrum hemp extracts.
Charlotte's Web (OTCQX:CWBHF) outlined diverging hemp policies as California's SB 378 takes effect on July 1, 2026, sharply limiting direct-to-consumer and online sales of ingestible full- and broad-spectrum hemp products and forcing the company to stop direct shipments of affected items to California customers.
Some topicals, cannabinoid isolates, and mushroom-based products may remain available, pending regulatory confirmation. At the same time, the White House on June 24, 2026 urged Congress to protect access to appropriate full-spectrum CBD products and consider delaying federal changes slated for November 12, 2026, which Charlotte's Web supports through its ONE HEMP coalition work.
Charlotte's Web (OTCQX:CWBHF) announced that co-founder Jared Stanley resigned from its Board on June 3, 2026, to focus on leading DeFloria, an affiliated FDA Phase 2 botanical drug venture. He will remain an advisor, Charlotte's Web stays a DeFloria co-founder and shareholder, and the Board now has six directors.
Charlotte's Web (OTCQX:CWBHF) appointed Jeff Raborn to its Board of Directors, effective May 28, 2026. Raborn was designated by BT DE Investments, a British American Tobacco (BAT) subsidiary, under a previously announced transaction that closed May 28, 2026.
Raborn is Executive Vice President, Law & External Affairs and General Counsel at Reynolds American, a BAT subsidiary, bringing more than 25 years of legal and regulatory experience. His appointment, made under an amended and restated investor rights agreement, is BAT's second board designation and increases Charlotte's Web's Board to seven directors.
Charlotte's Web (OTCQX:CWBHF) closed a transaction with British American Tobacco subsidiary BAT involving full conversion of a C$75.3 million debenture plus interest into equity and a concurrent US$10 million private placement, both at C$0.94 per share. The deal awaits final TSX approval.
BAT received 95,281,277 shares from the debenture conversion and subscribed for 14,662,765 additional shares. Net proceeds are intended to support Charlotte's Web’s participation in the anticipated CMMI Medicare CBD pilot program and other medical channel initiatives.